Vikas Londhe on Andexxa’s Safety Assessment Updates
Vikas Londhe, Chief Editor of Pharmacally.com, shared on LinkedIn:
”FDA Safety Update: Andexxa Risks Outweigh Benefits After Postmarketing Thromboembolic Events—Market Withdrawal Planned
FDA Updates Safety Assessment of Andexxa After Serious Thromboembolic Events.
On December 18, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication regarding Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo).
The agency has reviewed postmarketing safety data showing an increased incidence of thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa.
Based on these findings, the FDA now considers that the risks associated with Andexxa outweigh its benefits in its approved use.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Apr 9, 2026, 15:10Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?
-
Apr 9, 2026, 15:09National Institutes of Health Addresses VTE Research Funding Gap – JTH
-
Apr 9, 2026, 15:08Alice Assinger: Recruiting PhD Students for NET-IT Doctoral Program in Vienna
-
Apr 9, 2026, 15:07Hannah Cohen: A Novel Approach to Post-Stroke Gait Rehabilitation
-
Apr 9, 2026, 15:07Shehab Mohamed: A Single-Center Experience on Stroke Risk in Polycythemia Vera
-
Apr 9, 2026, 15:06Catch the Brand-New Recap of the Phase III OCEANIC-STROKE Trial – ISTH
-
Apr 9, 2026, 15:06Neeraj Jain: Building Capacity for Better Haemoglobinopathy Care in Maharashtra
-
Apr 9, 2026, 15:05Esther Nakkazi: Armenia Leads WHO Resolution to Advance Haemophilia Care Worldwide
-
Apr 9, 2026, 15:04Quintijn Bonnez: Detecting ADAMTS13 Structural Changes with Conformation-Sensitive Antibody 1C4